Single-agent anti-PD-1 immune checkpoint blockade (ICB) has become the standard of care in treatment of Canadian patients with metastatic non-small-cell lung cancer (mNSCLC) and PD-L1 tumor proportion score (TPS) expression ≥50% based on overall survival (OS) benefits and manageable toxicity profile [6,7]. This evidence concerns the gene CD274 and neoplasm.